Det ble stilt spørsmål om denne studien på Q3 2019. Se transcript under. Ett annet relevant spm er jo hvor langt frem i tid man har patent på fimaCHEM? Det vil jo potensielt kunne ta lang til å få godkjent ett nytt studie.
Unidentified Analyst, [55]
It’s about the head and neck study. So there’s been some quite interesting information coming out from other Norwegian company on the head and neck lately. Also very interesting to see that compared to the results you had, which I think it was about 80% of response rate compares very well to the checkpoint inhibitor results so far achieved. Can you comment on how close – if you see any prospects for opening up that study or – in a setting that you can come back to the head and neck in the future?
Per Walday, PCI Biotech Holding ASA - CEO [56]
I would not disregard that completely. I would say that we would not go back to do the head and neck study the way we did it, which was quite complicated study where you tried to ablate the whole tumor. But it is possible to do something in head and neck with this technology and combine it, for example, with checkpoint inhibitors, or actually using maybe even the fimaVACC technology and do intratumor vaccination, which we have very good preclinical results with and combining that with checkpoint inhibitors. So there are possibilities there that we can pursue, but we don’t have any plans currently to do it, and we don’t have funding to do it currently. So we’re right now focusing on achieving the bile duct cancer study and making sure that we have progress in that study and taking that to completion. And in parallel, we are assessing what other things it’s possible to do in the area.
Okay. Thank you very much for your attention and your time.
https://finance.yahoo.com/news/edited-transcript-pcib-ol-earnings-163323691.html
Edit: For min egen del gjør dette utsagnet til PW at verdiene av fimaVACC potensielt KAN bli høyere enn fimaCHEM på sikt.
